All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
DelveInsight’s “Parkinson’s Disease Psychosis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Parkinson’s Disease Psychosis, historical and forecasted epidemiology, as well as the Parkinson’s Disease Psychosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Parkinson’s Disease Psychosis Market Forecast @ https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-market
Key Takeaways from the Parkinson’s Disease Psychosis Market Report
* The total diagnosed prevalent cases of Parkinson’s disease in the 7MM were 2,718 thousand in 2023 and are expected to increase at a significant CAGR of throughout the forecast period.
* In 2023, Japan contributed 258 thousand diagnosed prevalent cases of Parkinson’s disease, representing almost 9% of the total diagnosed prevalence across the 7MM.
* Among the 7MM, EU4 and the UK accounted for nearly 353 thousand diagnosed prevalent cases of PDP, and these cases are expected to increase during the forecast period (2024-2034).
* Among EU4 and the UK, Germany had the highest diagnosed prevalent population of PDP, with 134 thousand cases, followed by France and Italy in 2023. On the other hand, the UK had the lowest diagnosed prevalent population in EU4 and the UK in 2023.
* In Japan, there were around 74 thousand diagnosed prevalent cases of PDP in 2023. These cases are expected to increase at a significant CAGR.
* The leading Parkinson’s Disease Psychosis Companies such as Enterin Inc., Otsuka Pharmaceutical Development & Commercialization Inc., ACADIA Pharmaceuticals Inc., Tasly Pharmaceutical Group Co., Ltd, and others.
* Promising Parkinson’s Disease Psychosis Therapies such as aripiprazole, Pimavanserin tartrate (ACP-103), pimavanserin tartrate, ACP-103 and others.
Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Parkinson’s Disease Psychosis Market Forecast. Click here to get more insights @ Parkinson’s Disease Psychosis Treatment Market Size
Parkinson’s Disease Psychosis Epidemiology Segmentation in the 7MM
* Total Parkinson’s Disease Psychosis Diagnosed Prevalent Cases
* Total Parkinson’s Disease Psychosis Treated Cases
Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Parkinson’s Disease Psychosis Market Forecast. Click here to shape the future @ Parkinson’s Disease Psychosis Prevalence
Parkinson’s Disease Psychosis Emerging Drugs
* ENT-012: Enterin Inc.
ENT-012 is undergoing Phase IIa clinical trials to evaluate its efficacy and safety in treating psychosis associated with Parkinson’s disease. This phase focuses on assessing the drug’s ability to reduce the severity of psychotic symptoms, measured through the Scale for the Assessment of Positive Symptoms (SAPS). Preliminary results suggest that ENT-012 is generally well-tolerated, with side effects similar to those of other SSRIs, such as gastrointestinal disturbances, headaches, and fatigue. The trial is designed to gather more comprehensive data on its impact on patients, and results are expected in the near future.
Parkinson’s Disease Psychosis Treatment Landscape
Symptomatic treatment is critical in managing Parkinson’s disease Psychosis, which often requires a careful balance between addressing psychotic symptoms and minimizing the exacerbation of motor issues commonly associated with Parkinson’s disease. Antipsychotic medications are frequently prescribed, but many traditional options can worsen motor symptoms, making the choice of treatment particularly challenging. As a result, newer medications like ENT-012, a selective serotonin reuptake inhibitor, are being explored to provide effective symptom relief without negatively impacting motor function. Overall, the treatment landscape for Parkinson’s disease Psychosis is marked by a combination of symptomatic management, ongoing research, and supportive care. While there is currently no definitive cure, advancements in Parkinson’s disease Psychosis clinical trials and emerging therapies offer hope for more effective and targeted treatment strategies in the future. Collaborative efforts among healthcare professionals, researchers, and patient organizations are crucial in improving outcomes for individuals affected by this challenging condition. The total market size of the PDP treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments.
Discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Parkinson’s Disease Psychosis Market Forecast. Click here @ Parkinson’s Disease Psychosis Ongoing Clinical Trials Assessment
Parkinson’s Disease Psychosis Market Outlook
Parkinson’s disease Psychosis (PDP) is a complex condition characterized by the emergence of psychotic symptoms, such as hallucinations and delusions, in patients with Parkinson’s disease. The treatment landscape for PDP is still evolving, as the interplay between neurodegeneration and psychosis complicates the establishment of standardized treatment protocols. Currently, there are no universally approved therapies specifically for PDP, and management primarily focuses on alleviating symptoms while ensuring the patient’s overall well-being. Ongoing research into the underlying mechanisms of Parkinson’s disease Psychosis is paving the way for innovative treatment options. Investigational therapies, including ENT-012, are being evaluated in clinical trials to determine their effectiveness and safety. These efforts aim to identify new pharmacological approaches that specifically target the serotonergic system to mitigate psychotic symptoms more effectively.
Parkinson’s Disease Psychosis Companies
Enterin Inc., Otsuka Pharmaceutical Development & Commercialization Inc., ACADIA Pharmaceuticals Inc., Tasly Pharmaceutical Group Co., Ltd, and others.
Explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Parkinson’s Disease Psychosis Market Forecast. Click here to lead in advancements @ Parkinson’s Disease Psychosis Market Drivers and Barriers
Scope of the Parkinson’s Disease Psychosis Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Parkinson’s Disease Psychosis Companies- Enterin Inc., Otsuka Pharmaceutical Development & Commercialization Inc., ACADIA Pharmaceuticals Inc., Tasly Pharmaceutical Group Co., Ltd, and others.
* Parkinson’s Disease Psychosis Therapies- aripiprazole, Pimavanserin tartrate (ACP-103), pimavanserin tartrate, ACP-103 and others.
* Parkinson’s Disease Psychosis Therapeutic Assessment: Parkinson’s Disease Psychosis current marketed and Parkinson’s Disease Psychosis emerging therapies
* Parkinson’s Disease Psychosis Market Dynamics: Parkinson’s Disease Psychosis market drivers and Parkinson’s Disease Psychosis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
* Parkinson’s Disease Psychosis Unmet Needs, KOL’s views, Analyst’s views, Parkinson’s Disease Psychosis Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Parkinson’s Disease Psychosis Market Report Introduction
3. Parkinson’s Disease Psychosis Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Executive Summary
6. Key Events
7. Parkinson’s Disease Psychosis Disease Background and Overview
8. Parkinson’s Disease Psychosis Epidemiology and Patient Population
9. Parkinson’s Disease Psychosis Patient Journey
10. Parkinson’s Disease Psychosis Emerging Therapies
10.1. Key Cross-Competition of Emerging Drugs
11. Parkinson’s Disease Psychosis Marketed Therapies
12. Parkinson’s Disease Psychosis: Market Analysis
13. Key Opinion Leaders’ Views
14. Parkinson’s Disease Psychosis SWOT Analysis
15. Parkinson’s Disease Psychosis Unmet Needs
16. Parkinson’s Disease Psychosis Market Access and Reimbursement
17. Appendix
18: DelveInsight Capabilities
19: Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-market
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Parkinson’s Disease Psychosis Market Size in the 7MM was ~USD 665 million in 2023 and It is projected to grow by 2034, estimates DelveInsight
